The AstraZeneca share price is rising fast. Here’s what I’d do now

FTSE 100 pharmaceuticals giant AstraZeneca turned in a good set of results. Is it time to buy right now?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE 100 pharmaceuticals giant AstraZeneca (LSE: AZN) share price was a big gainer yesterday, rising by 5.5% from the day before as it reported a healthy set of results. Its share price is now close to all-time highs, raising the question – Is this a good time to buy AZN?

Expensive but worthy

I find it helpful to look at the price-to-earnings ratio (P/E) when share prices are rising to get a sense of how expensive the stock really is. From the looks of it, AZN sure is highly priced. Its 12-month trailing P/E is almost 43x compared to 19x for another FTSE 100 pharmaceuticals peer GlaxoSmithKline (GSK). Not to undermine GSK’s value, but I think this is a case of investors putting a premium on AZN rather than a one-off spike in its P/E, considering that it’s been maintained for some time now.

It was my top share for May, after it reported a good set of numbers and my sense was that it would rise from there on. From the time the article was published to now, the share price is up 31% and interestingly enough, the P/E is actually marginally lower than the 45x seen then. As an investor, this tells me that there are capital gains to be made even if the ratio is high, instructive as it is. Also, a high ratio doesn’t indicate that the share price will come off soon. In other words, don’t let a high P/E deter you right now because there are enough reasons that still make AZN attractive.  

Safe haven

It’s a big pharmaceuticals company in an economic environment that continues to look uncertain. A number of other defensive shares have also seen a great run-up in share prices in recent years and AZN is no exception. Its international focus also helps, since it’s not entirely vulnerable to the UK’s fortunes. In the latest earnings release, CEO Pascal Soriot noted “impressive results” in international markets like China, the US and Japan.

Performance boost

Besides this, yesterday’s results showed an 18% increase in product sales at constant exchange rate and core operating profit grew by 41% in the third quarter of 2019. The numbers look good on a year-to-date basis too. I also like that AZN has actually upgraded its sales guidance for the second straight quarter, which basically means that it is expected to continue performing going forward.

Coming back to the original question – should I buy AZN shares now, even with the price rise? I reckon that its share price will rise higher over time if things continue to go the way they are right now. Since we at the Motley Fool are concerned with long-term investments, now is as good a time as any other to buy the share. As is the nature of share prices, there will most likely be short-term dips in the near future, and that should be an opportunity to buy more of AZN. But some can be bought right away, I believe.

Manika Premsingh has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

ChatGPT thinks these are the 5 best FTSE stocks to consider buying for 2026!

Can the AI bot come up trumps when asked to select the best FTSE stocks to buy as we enter…

Read more »

Investing For Beginners

How much do you need in an ISA to make the average UK salary in passive income?

Jon Smith runs through how an ISA can help to yield substantial income for a patient long-term investor, and includes…

Read more »

Investing Articles

3 FTSE 250 shares to consider for income, growth, and value in 2026!

As the dawn of a new year in the stock market approaches, our writer eyes a trio of FTSE 250…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Want to be a hit in the stock market? Here are 3 things super-successful investors do

Dreaming of strong performance when investing in the stock market? Christopher Ruane shares a trio of approaches used by some…

Read more »

Two white male workmen working on site at an oil rig
Investing Articles

The BP share price has been on a roller coaster, but where will it go next?

Analysts remain upbeat about 2026 prospects for the BP share price, even as an oil glut threatens and the price…

Read more »

Investing Articles

Prediction: move over Rolls-Royce, the BAE share price could climb another 45% in 2026

The BAE Systems share price has had a cracking run in 2025, but might the optimism be starting to slip…

Read more »

Tesla car at super charger station
Investing Articles

Will 2026 be make-or-break for the Tesla share price?

So what about the Tesla share price: does it indicate a long-term must-buy tech marvel, or a money pit for…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

Apple CEO Tim Cook just put $3m into this S&P 500 stock! Time to buy?

One household-name S&P 500 stock has crashed 65% inside five years. Yet Apple's billionaire CEO sees value and has been…

Read more »